Cover Image

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections

Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is limited, and only a few cases have performed...

Full description

Saved in:

Bibliographic Details
Main Authors:	Altea Gallerani (Author), Milo Gatti (Author), Andrea Bedini (Author), Stefania Casolari (Author), Gabriella Orlando (Author), Cinzia Puzzolante (Author), Erica Franceschini (Author), Marianna Menozzi (Author), Antonella Santoro (Author), Nicole Barp (Author), Sara Volpi (Author), Alessandra Soffritti (Author), Federico Pea (Author), Cristina Mussini (Author), Marianna Meschiari (Author)
Format:	Book
Published:	MDPI AG, 2023-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Is It Possible to Eradicate Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) from Endemic Hospitals?
by: Filippo Medioli, et al.
Published: (2022)

Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients
by: Gaetano Alfano, et al.
Published: (2021)

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring
by: Pier Giorgio Cojutti, et al.
Published: (2022)

Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015-2021)
by: Marianna Meschiari, et al.
Published: (2022)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
by: Luis Buzón-Martín, et al.
Published: (2021)

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature
by: Giulia Jole Burastero, et al.
Published: (2022)

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections
by: Rossella Barone, et al.
Published: (2023)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
by: Andrés Ruiz-Sancho, et al.
Published: (2023)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience
by: Maria Mazzitelli, et al.
Published: (2022)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
by: Gatti M, et al.
Published: (2021)

Pharmacokinetic/pharmacodynamic issues for optimizing treatment with beta-lactams of Gram-negative infections in critically ill orthotopic liver transplant recipients: a comprehensive review
by: Milo Gatti, et al.
Published: (2024)

A Retrospective Whole-Genome Sequencing Analysis of Carbapenem and Colistin-Resistant <i>Klebsiella pneumoniae</i> Nosocomial Strains Isolated during an MDR Surveillance Program
by: Bernardina Gentile, et al.
Published: (2020)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2022)

Dalbavancin in the treatment of skin and soft tissues infection
by: Ana Candela Fajardo, et al.
Published: (2017)

Evaluating the Use of Dalbavancin for Off-Label Indications
by: Katherine Taylor, et al.
Published: (2022)

Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an <i>In Vitro</i> Study
by: Mar Sánchez-Somolinos, et al.
Published: (2022)

Dalbavancin in Bone and Joint Infections: A Systematic Review
by: Sofia Lovatti, et al.
Published: (2023)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
by: Leama Ajaka, et al.
Published: (2020)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
by: Simonetti O, et al.
Published: (2021)

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections
by: Dimitra Dimopoulou, et al.
Published: (2023)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
by: Jason W Bennett, et al.
Published: (2008)

Acute myocarditis as the main clinical manifestation of SARS-CoV 2 infection: A case report
by: Gianluca Cuomo, et al.
Published: (2020)

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience
by: Dario Cattaneo, et al.
Published: (2023)

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Dalbavancin
by: Ute Chiriac, et al.
Published: (2022)

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> in Critically Ill Adult Patients
by: Milo Gatti, et al.
Published: (2021)

Effectiveness of alveolar preservation techniques for prosthetic and impant-prosthetic rehabilitations
by: Orlando Guerra Cobian, et al.
Published: (2018)

Migration and health: A retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived migrants screened at the Infectious Diseases Unit of Modena, Italy
by: Gianluca Cuomo, et al.
Published: (2019)

Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
by: Jessica J. Tuan, et al.
Published: (2022)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
by: Leuthner KD, et al.
Published: (2016)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
by: Giacomo Stroffolini, et al.
Published: (2022)

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?
by: Milo Gatti, et al.
Published: (2023)

Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP
by: Milo Gatti, et al.
Published: (2024)

Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections
by: Milo Gatti, et al.
Published: (2023)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022)

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
by: Milo Gatti, et al.
Published: (2023)

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series
by: Connor Evins, et al.
Published: (2022)

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
by: Lucia Brescini, et al.
Published: (2021)

In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
by: Mar Sánchez-Somolinos, et al.
Published: (2023)

Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study
by: Thamer A. Almangour, et al.
Published: (2020)